Market Snapshot

S&P Futures
4,114.00
Dow Futures
33,641.00
NASDAQ Futures
13,811.00

7.34$-0.14 -1.80%
At close    04:00 PM   
From: To:

Stock Snapshot

7.18
Prev. Close
7.41
Open
369.44M
Market Cap
2.09M
Number of Shares
7.27
Day Low
7.53
Day High
7.34
-
P/E Ratio
29.56M
Free Float in %
-2.81
EPS 2021
4.08
Book Value per Share
4.40
Cash Flow per Share
Homology Medicines, Inc. (FIXX)
Homology Medicines, Inc. (FIXX) stock rallied over -1.80% intraday to trade at $7.34 per share on NASDAQ. The stock opened with a gain of 3.20% at $7.41 and touched an intraday high of $7.53, rising 4.87% against the last close of $7.18. The stock went to a low of $7.27 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-04-09$7.41$7.32$7.32$7.53$7.271,092,200
2021-04-08$7.26$7.48$7.48$7.50$7.142,154,400
2021-04-07$7.90$7.18$7.18$7.93$7.186,149,700
2021-04-06$9.56$9.30$9.30$9.65$9.25485,900
2021-04-05$9.78$9.64$9.64$9.83$9.55273,200
2021-04-01$9.50$9.62$9.62$9.73$9.43445,100
2021-03-31$9.41$9.41$9.41$9.60$9.29272,400
2021-03-30$9.17$9.28$9.28$9.40$8.90250,700
2021-03-29$9.54$9.17$9.17$9.74$9.15320,800
2021-03-26$9.57$9.54$9.54$9.67$9.24510,800
2021-03-25$9.40$9.54$9.54$9.56$9.06310,400
Homology Medicines, Inc.
One Patriots Park
Bedford, MA 01730
United States

http://www.homologymedicines.com
781 301 7277
Employees
205
Sector
Healthcare
Sales or Revenue
2.70M
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30
Dr. Arthur O. Tzianabos
Pres, CEO & Director
Mr. W. Bradford Smith
CFO, Treasurer & Sec.
Dr. Albert Seymour Ph.D.
Chief Scientific Officer
Homology Medicines, Inc.
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.